Atrial Fibrillation Clinical Trial
Official title:
CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study.
Study design:
Randomized prospective comparison of pulmonary vein isolation alone versus a strategy aiming
for atrial fibrillation termination by using a stepwise approach consisting of pulmonary vein
isolation, biatrial defragmentation aiming for fractionated electrograms and linear ablation
if required.
Study protocol:
In patients randomized to PVI alone, the index procedure consists of wide circumferential
pulmonary vein isolation (1 cm distal of the PV ostium) including optional right atrial
isthmus ablation. Endpoint for PVI is entrance block as evaluated by a circumferential
mapping catheter during sinus rhythm at the end of the procedure. In all patients the NavX®
three-dimensional mapping system should be used. The St. Jude Medical Coolflex® or Coolpath®
catheters may be used at the operator's discretion.
In patients randomized to the strategy aiming for atrial fibrillation termination PVI is also
the initial step of the procedure followed by atrial defragmentation and eventual linear
ablation in case of atrial tachycardia aiming for acute restoration of sinus rhythm. The
procedural steps with regard to mapping and ablation of atrial fibrillation and consecutive
atrial tachycardia follow the previously described methods (8,9). After initial ablation the
previous antiarrhythmic drug treatment can be continued but no de novo antiarrhythmic drug
regiment should be applied. The primary endpoint of this study is recurrence of atrial
arrhythmias between 6 and 12 months after the initial ablation procedure.
In both study arms, the same CE certified catheters will be used. Usually, the setting
consists of on decapolar catheter positioned in the coronary sinus, one circumferential
mapping catheters for mapping of the pulmonary veins, one quadripolar catheter for mapping
the right atrium. In both study groups a externally irrigated catheter for mapping and
ablation will be used (CoolFlex/ Coolpath as mentioned above).
Sample size calculation:
According to the assumption of a difference of 30 % regarding the primary endpoint (power 80,
alpha=0.05) 70 patients have to be included. Considering a potential drop out of 10 % 160
patients should be included. However, an adaptive statistical plan is applied (Prof.
Wegscheider, University Hospital Hamburg).
Follow up and repeat procedures:
Crossover between the two treatment options should be avoided. Previous antiarrhythmic drug
treatment can be continued until month 6 after the index procedure is completed. Repeat
procedures between month 0 and 3 should be avoided. Repeat procedures should be planned
between month 3 and 6 after the index procedure. The initial approach of the repeat procedure
is the same as during the index procedure (Figure 1). Thus, in patients randomized for PVI
alone, PVI will be repeated in case of reconnection of the veins. In the setting of complete
block of all pulmonary veins also patients randomized to PVI alone will receive a substrate
modification as in the other group. Patients randomized to the ablation procedure aiming for
AF termination will again receive a 'complete' procedure including assessment of PVI and
ablation of atrial tachycardias and atrial fibrillation.
Follow-up:
All patients will be seen in the outpatient clinic every 3 month during the 12 month study
period. The visit will include ECG and Holter ECG recordings. Additionally, echocardiography
and interrogation of pacemaker will be performed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |